Our Commitment to Excellence in Gene Therapy
We bridge the gap between breakthrough science and therapeutic reality, delivering first-in-class AAV-based solutions for rare human genetic disorders and innovative veterinary health.
We are dedicated to pioneering high-precision pharmaceutical solutions that redefine health standards. Through rigorous clinical adherence and strategic industrial partnerships, we deliver safe, effective, and transformative medications to patients and the veterinary community globally.
Current Medicine Pipeline
DRP-101
A first-in-class AAV-based gene therapy designed to restore telomere homeostasis and reverse the accelerated aging phenotype of Werner Syndrome. By delivering coordinated telomerase factors, we enable cellular rejuvenation without loss of patient cell identity.
DRP-102A
An innovative veterinary gene therapy developed to eliminate the Fel d 1 allergen at its genetic source. Utilizing CRISPR-Cas9 gene editing, we selectively disable the feline genes responsible for allergen production, offering a durable solution for feline-human coexistence.
Quality & Innovation
ADVANCED AAV VECTOR MANUFACTURING
Our world-class facility, operated by DrPark CDMO Korea, represents the pinnacle of viral vector production. By integrating industrial-grade precision with proprietary bioprocessing technology, we ensure the safety, scalability, and clinical reliability of every next-generation gene therapy platform we develop.
Global Inquiries & Partnerships
USA & South Korea
DrPark Pharmaceutical Inc is pharmaceutical arm of Dr.Park CDMO which is biomedical corridor of Korea, operating in direct coordination with our cutting edge CDMO Manufacturing facility to deliver precision AAV-based therapies.
Stakeholder Relations
We prioritize transparent communication with our clinical partners and stakeholders. For regulatory data or institutional collaboration requests, please utilize the secure coordination portal.